SPRO — Spero Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1701108 ·
Last close
$0.90
Market Cap
$52.51M
52W High
$3.08
52W Low
$0.88
ADV30
366,985
Next earnings
2026-11-12
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -6,913,000 -44,278,000 110,026,000 107,928,000 109,245,000
Jun 2026 0 — -9,926,000 -9,552,000 52,766,000 50,774,000 8,562,000
Mar 2026 258,000 — -7,538,000 -7,203,000 59,021,000 56,129,000 6,087,000
Dec 2025 39,658,000 — 31,405,000 31,520,000 68,919,000 40,265,000 9,898,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$19,580,000
Investing CF
—
Financing CF
—
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.11
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-467,821,000
Inventory
—
Receivables
$25,000
ST Investments
—
EBIT TTM
$6,612,000
Pretax Income TTM
$7,644,000
Interest Exp TTM
—
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$46,997,000
EBITDA
—
Free Cash Flow
$28,848,500
Enterprise Value
$9,503,827
Total Cash
$50,774,000
Total Debt
$2,043,000
Shares Out
58,264,577
Trailing EPS
$-0.50
Book Value
$1.05
ROE
19.2%
ROA
7.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 59,619,000 7,159,000 8,572,000 68,919,000 9,898,000 59,021,000 -12,624,000
Dec 2024 27,396,000 -72,484,000 -68,566,000 110,543,000 64,420,000 46,123,000 -23,444,000
Dec 2023 96,735,000 26,787,000 22,806,000 182,390,000 75,496,000 106,894,000 -32,995,000
Dec 2022 48,579,000 -30,567,000 -46,415,000 124,802,000 48,868,000 75,934,000 -7,731,000

TTM Snapshot

Revenues TTM
$46,997,000
NetIncome TTM
$7,383,000
OpCashFlow TTM
—
Assets (Latest)
$52,766,000
Forward EPS
$-0.98

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $1.50 · spot: $0.87 · call volume: 11 · put volume: 1,020
Expected Move to 2027-01-15: ±$0.65 (74.37%) — implied range $0.22 – $1.52 · ATM straddle on $1.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
GANX Gain Therapeutics, Inc. $52.54M $1.18 —
AZR Azora Therapeutics, Inc. (DE) $52.36M $3.66 —
IBIO iBio, Inc. $52.71M $0.75 —
XLO Xilio Therapeutics, Inc. $53.26M $7.54 —
IBO IMPACT BIOMEDICAL INC. $53.31M $6.17 —

News headlines (Yahoo Finance, 1h cache)

Spero Therapeutics Announces Third Quarter 2026 Operating Results and Provides Business Update
2026-11-12 21:05 · Yahoo
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-11-04 21:05 · Yahoo
Spero Therapeutics to Present at Investor Conferences in November
2026-11-02 21:05 · Yahoo
Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline
2026-10-26 12:00 · Yahoo
Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related Disease
2026-10-21 06:02 · Yahoo
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
2026-10-15 20:05 · Yahoo
Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | Delv
2026-10-12 17:00 · Yahoo
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-02 20:05 · Yahoo
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
2026-09-02 20:01 · Yahoo
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript
2026-08-19 21:28 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.